NKGen Biotech Welcomes New Directors and Assigns Committees

NKGen Biotech ( (NKGN) ) just unveiled an update.

NKGen Biotech Inc. has announced the appointment of Michael Klowden and Kathleen Scott as new directors following their respective resignations. Klowden will serve as a Class II director until the 2025 stockholders’ meeting, while Scott will be a Class III director until the 2026 meeting. Both are also taking on key committee roles, with Klowden chairing the Nomination and Corporate Governance Committee and Scott leading the Audit and Compensation Committees. They’ll receive the standard compensation for non-employee directors, deferred until the company achieves certain financial milestones. No conflicts of interest were reported in their appointments.

For a thorough assessment of NKGN stock, go to TipRanks’ Stock Analysis page.